Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL

Diabetes Care

Volumn 34, Issue 12, 2011, Pages 2576-2580

  Wang, Yanan ^a   Snel, Marieke ^a   Jonker, Jacqueline T ^a   Hammer, Sebastiaan ^a   Lamb, Hildo J ^a   De Roos, Albert ^a   Meinders, A Edo ^a   Pijl, Hanno ^a   Romijn, Johannes A ^a   Smit, Johannes W A ^a   Jazet, Ingrid M ^a   Rensen, Patrick C N ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL; CETP PROTEIN, HUMAN; CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; LOW CALORY DIET; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; VERY LOW CALORIE DIET; BLOOD; DIET THERAPY; METABOLISM; MIDDLE AGED;

APOLIPOPROTEIN A-I; CALORIC RESTRICTION; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OBESITY; TRIGLYCERIDES;

EID: 84860858861     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0685     Document Type: Article

References (23)

1. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191:235-240 (Pubitemid 46400718)
2. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-1953
3. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285: E906-E916 (Pubitemid 37176440)
4. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854-858 (Pubitemid 39093200)
5. Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002;2:210-215
6. de Haan W, van der Hoogt CC, Westerterp M, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 2008;197:57-63 (Pubitemid 351273273)
7. van der Hoogt CC, de Haan W, Westerterp M, et al. Fenofibrate increases HDLcholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res 2007;48:1763-1771 (Pubitemid 47311993)
8. van der Hoorn JW, de Haan W, Berbée JF, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008;28:2016-2022
9. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009;119:2069-2077
10. Jonker JT, Wang Y, de Haan W, et al. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes. Diabetes Care 2010;33:1625-1628
11. Hammer S, Snel M, Lamb HJ, et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008;52:1006-1012
12. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000;105:513-520 (Pubitemid 30127252)
13. Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 1992;90:1290-1295
14. Laimer MW, Engl J, Tschoner A, et al. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 2009;44:1125-1130
15. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA 2004;101:6659-6663 (Pubitemid 38586030)
16. Verdery RB, Walford RL. Changes in plasma lipids and lipoproteins in humans during a 2-year period of dietary restriction in Biosphere 2. Arch Intern Med 1998;158: 900-906 (Pubitemid 28183646)
17. Walford RL, Harris SB, Gunion MW. The calorically restricted low-fat nutrientdense diet in Biosphere 2 significantly lowers blood glucose, total leukocyte count, cholesterol, and blood pressure in humans. Proc Natl Acad Sci USA 1992;89:11533-11537
18. Tapsell L, Batterham M, Huang XF, et al. Short term effects of energy restriction and dietary fat sub-type on weight loss and disease risk factors. Nutr Metab Cardiovasc Dis 2010;20:317-325
19. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358: 2026-2033 (Pubitemid 34084825)
20. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem2000;275:33053-33058
21. Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic ABCA1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005;115:1333-1342 (Pubitemid 40629053)
22. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar highdensity lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010;30:796-801
23. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, highdensity lipoprotein function, and atherosclerosis. N Engl J Med 2011;364: 127-135